Deutsche Märkte öffnen in 8 Stunden 23 Minuten

Epizyme, Inc. (EPZM)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
12,62+0,20 (+1,61%)
Börsenschluss: 4:00PM EDT

12,62 0,00 (0,00 %)
Nachbörse: 4:02PM EDT

Epizyme, Inc.

400 Technology Square
4th Floor
Cambridge, MA 02139
United States
617 229 5872
http://www.epizyme.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter203

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Robert B. Bazemore Jr.Pres, CEO, Sec. & Director1,01MN/A1968
Mr. Paolo TombesiChief Financial Officer628,41kN/A1964
Mr. Matthew E. RosExec. VP and Chief Strategy & Bus. Officer644,06kN/A1967
Dr. Shefali Agarwal M.D., MPHChief Medical Officer737,27kN/A1974
Dr. H. Robert HorvitzCo-Founder & Chairman of the Scientific Advisory BoardN/AN/AN/A
Dr. Yi ZhangScientific Co-Founder & Member of The Scientific Advisory BoardN/AN/AN/A
Mr. Joseph BeaulieuController, Treasurer & Principal Accounting OfficerN/AN/A1981
Dr. Jeffery L. KutokChief Scientific OfficerN/AN/A1967
Jason FredetteVP of Investor RelationsN/AN/AN/A
Mr. John F. WeidenbruchGen. CounselN/AN/A1961
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Epizyme, Inc.s ISS Governance QualityScore, Stand 31. Oktober 2019, lautet 7. Die grundlegenden Scores sind Audit: 1, Vorstand: 6, Shareholderrechte: 7, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.